Canada’s regulatory approach to drugs for rare diseases: orphan drugs

Canada's regulatory approach: Drugs for rare diseases are authorized for sale in Canada under the Food and Drugs Act and Part C of the Food and Drug Regulations.

Data and Resources

Additional Info

Field Value
Last Updated April 17, 2026, 21:23 (UTC)
Created April 17, 2026, 21:23 (UTC)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2022-04-01 00:00:00
open_canada_keywords {"fr": ["Approche réglementaire du Canada", "médicaments contre les maladies rares", "médicaments orphelins"], "en": ["Canada’s regulatory approach", "drugs for rare-diseases", "orphan drugs"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Approche du Canada en matière de réglementation des médicaments utilisés pour soigner les maladies rares : les médicaments orphelins
update_frequency as_needed